RU2609661C2 - Антигенные композиции респираторного синцитиального вируса и способы - Google Patents

Антигенные композиции респираторного синцитиального вируса и способы Download PDF

Info

Publication number
RU2609661C2
RU2609661C2 RU2013101972A RU2013101972A RU2609661C2 RU 2609661 C2 RU2609661 C2 RU 2609661C2 RU 2013101972 A RU2013101972 A RU 2013101972A RU 2013101972 A RU2013101972 A RU 2013101972A RU 2609661 C2 RU2609661 C2 RU 2609661C2
Authority
RU
Russia
Prior art keywords
rsv
polypeptide
epitope
polyelectrolytes
peptide
Prior art date
Application number
RU2013101972A
Other languages
English (en)
Russian (ru)
Other versions
RU2013101972A (ru
Inventor
Томас Дж. ПАУЭЛЛ
Джеймс Горхам БОЙД
Original Assignee
Артифишэл Селл Технолоджис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Артифишэл Селл Технолоджис, Инк. filed Critical Артифишэл Селл Технолоджис, Инк.
Publication of RU2013101972A publication Critical patent/RU2013101972A/ru
Application granted granted Critical
Publication of RU2609661C2 publication Critical patent/RU2609661C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
RU2013101972A 2010-07-07 2011-07-07 Антигенные композиции респираторного синцитиального вируса и способы RU2609661C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36202910P 2010-07-07 2010-07-07
US61/362,029 2010-07-07
US201161485669P 2011-05-13 2011-05-13
US61/485,669 2011-05-13
PCT/US2011/043136 WO2012006395A1 (en) 2010-07-07 2011-07-07 Respiratory syncytial virus antigenic compositions and methods

Publications (2)

Publication Number Publication Date
RU2013101972A RU2013101972A (ru) 2014-08-20
RU2609661C2 true RU2609661C2 (ru) 2017-02-02

Family

ID=45438747

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013101972A RU2609661C2 (ru) 2010-07-07 2011-07-07 Антигенные композиции респираторного синцитиального вируса и способы

Country Status (13)

Country Link
US (1) US9487593B2 (enExample)
EP (1) EP2590675B1 (enExample)
JP (1) JP5890407B2 (enExample)
CN (2) CN106008716B (enExample)
AU (1) AU2011276251B2 (enExample)
BR (1) BR112013000345B1 (enExample)
CA (1) CA2799934C (enExample)
DK (1) DK2590675T3 (enExample)
ES (1) ES2688993T3 (enExample)
IL (1) IL222723B (enExample)
MX (1) MX340796B (enExample)
RU (1) RU2609661C2 (enExample)
WO (1) WO2012006395A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9433671B2 (en) 2012-03-30 2016-09-06 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US8883717B2 (en) 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods
WO2014019718A1 (en) 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
JP6553033B2 (ja) * 2013-08-13 2019-07-31 ノースウェスタン ユニバーシティ ペプチドコンジュゲート粒子
US9975066B2 (en) 2014-05-27 2018-05-22 Artificial Cell Technologies, Inc. Automated layer by layer construction of multilayer coated cores by TFF
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP6934862B2 (ja) 2015-09-16 2021-09-15 アーティフィシャル セル テクノロジーズ インコーポレイテッド 抗マラリア組成物および方法
US20170230649A1 (en) * 2016-02-05 2017-08-10 Qualcomm Incorporated Calibration of hybrid auto focus (af) imaging systems
LT3606942T (lt) 2017-04-04 2025-10-10 Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas
WO2019075400A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc CONFORMATIONAL EPITOPES IN A CENTRAL PROTECTED REGION OF SYNCYTIAL RESPIRATORY VIRUS PROTEIN G
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
JP2021534239A (ja) 2018-08-08 2021-12-09 トレリス・バイオサイエンス，エルエルシー Ｒｓｖの改善された受動的および能動的ワクチン
US20230414526A1 (en) * 2022-03-29 2023-12-28 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU96105905A (ru) * 1993-08-06 1998-06-10 Коннот Лабораториз Лимитед Инактивированные вакцины респираторно-синцитиального вируса
WO2006023029A2 (en) * 2004-06-16 2006-03-02 The Johns Hopkins University The cysteine-rich region of respiratory syncytial virus and methods of use therefor
EP2058002A1 (en) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
WO2009079066A2 (en) * 2007-09-26 2009-06-25 Aparna Biosciences Therapeutic and vaccine polyelectrolyte nanoparticle compositions
US20100028448A1 (en) * 2005-10-25 2010-02-04 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
US7723294B2 (en) * 2007-04-02 2010-05-25 Artificial Cell Technologies, Inc. Polypeptide films and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2167274C (en) * 1993-08-06 2007-11-27 Sonia E. Sanhueza Inactivated respiratory syncytial viral vaccines
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
CA2198279A1 (en) 1994-08-25 1996-02-29 Johannes Petrus Maria Langedijk Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection
FR2726471B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
ATE412666T1 (de) 2000-10-18 2008-11-15 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
AUPR520201A0 (en) 2001-05-23 2001-06-14 Commonwealth Scientific And Industrial Research Organisation Antiviral compounds
JP3997930B2 (ja) 2003-02-27 2007-10-24 富士ゼロックス株式会社 カーボンナノチューブの製造装置および製造方法
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US7348399B2 (en) * 2003-08-29 2008-03-25 Louisiana Tech University Foundation, Inc. Nanofabricated polypeptide multilayer films, coatings, and microcapsules
US7615530B2 (en) 2003-08-29 2009-11-10 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
US20080131450A1 (en) 2004-07-23 2008-06-05 Pierre Fabre Medicament Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions
WO2006079928A2 (en) * 2005-01-31 2006-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Polyelectrolyte multilayer film, preparation and uses thereof
WO2006108226A1 (en) * 2005-04-12 2006-10-19 The University Of Queensland Vaccine delivery system
EP1972348A1 (en) 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
US20100203071A1 (en) 2007-03-21 2010-08-12 Norman Blais Chimeric antigens
KR20110045008A (ko) 2008-07-18 2011-05-03 아이디 바이오메디컬 코포레이션 오브 퀘벡 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원
US20110318376A1 (en) 2008-12-24 2011-12-29 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
US8883717B2 (en) * 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU96105905A (ru) * 1993-08-06 1998-06-10 Коннот Лабораториз Лимитед Инактивированные вакцины респираторно-синцитиального вируса
WO2006023029A2 (en) * 2004-06-16 2006-03-02 The Johns Hopkins University The cysteine-rich region of respiratory syncytial virus and methods of use therefor
US20100028448A1 (en) * 2005-10-25 2010-02-04 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
US7723294B2 (en) * 2007-04-02 2010-05-25 Artificial Cell Technologies, Inc. Polypeptide films and methods
WO2009079066A2 (en) * 2007-09-26 2009-06-25 Aparna Biosciences Therapeutic and vaccine polyelectrolyte nanoparticle compositions
EP2058002A1 (en) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG-FA FAN, XING-GUO MEI, "Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response." Vaccine, 2005, 23(35): 4453-4461. *
CHOUNG S.-F. et al., "A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules", Biomaterials, 2009; 30(28): 5178-5186. *
ZENG RUI-HONG et al. "Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope", Vaccine, 2006; 24(7): 941-947. *

Also Published As

Publication number Publication date
RU2013101972A (ru) 2014-08-20
JP2013535428A (ja) 2013-09-12
CN106008716A (zh) 2016-10-12
AU2011276251A2 (en) 2013-01-24
EP2590675B1 (en) 2018-08-29
US9487593B2 (en) 2016-11-08
CA2799934A1 (en) 2012-01-12
EP2590675A1 (en) 2013-05-15
JP5890407B2 (ja) 2016-03-22
CA2799934C (en) 2020-01-28
DK2590675T3 (en) 2018-10-29
MX2012015030A (es) 2013-06-13
IL222723B (en) 2020-03-31
CN103037898B (zh) 2016-06-29
MX340796B (es) 2016-07-27
BR112013000345A2 (pt) 2016-05-31
BR112013000345B1 (pt) 2021-11-23
CN106008716B (zh) 2019-08-13
AU2011276251A1 (en) 2012-11-08
CN103037898A (zh) 2013-04-10
AU2011276251B2 (en) 2015-02-05
IL222723A0 (en) 2012-12-31
WO2012006395A1 (en) 2012-01-12
US20120009254A1 (en) 2012-01-12
ES2688993T3 (es) 2018-11-07

Similar Documents

Publication Publication Date Title
RU2609661C2 (ru) Антигенные композиции респираторного синцитиального вируса и способы
AU2013240105B2 (en) Microparticle vaccine against malaria
US10588954B2 (en) Anti-malaria compositions and methods
US20230414526A1 (en) Respiratory syncytial virus antigenic compositions and methods
CA3112575A1 (en) Anti-malaria compositions and methods
HK1206972B (en) Microparticle/nanoparticle vaccine against malaria